Live
- Congress Challenges PM Modi's Allegations: Calls Out "Falsehoods" Amidst Electoral Rhetoric
- CPI(M) leader seeks Calcutta HC’s attention over Bengal CM's anti-judiciary comments
- Aparna Yadav Challenges Akhilesh Yadav's Candidacy In Kannauj: No Longer A Smooth Ride For Samajwadi Party
- A constable who helped an old woman in a very dangerous place
- WBSSC Claims Eligibility For 19,000 Dismissed Staff Amidst Teacher Recruitment Scandal
- Tollywood’s shifting landscape: The growing influence of OTT platforms
- YSR Congress Party MLA candidate KK Raju campaigns in 23rd Ward Priyadarshini Colony
- Leaders and Residents Welcome TDP Candidates Pulivarthi Nani and Daggumalla Prasada Rao in Tirupati
- 30 Families Switch Allegiance from YSR Congress to Telugu Desam Party in Batladinne Village
- Mannara Chopra’s refreshing photoshoot brings summer vibes
Suven gets patent for neurological molecule
Suven Life Sciences has received a patent approval by Singapore corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
Hyderabad: Suven Life Sciences has received a patent approval by Singapore corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
According to a company’s communique to BSE, “the patent is valid till 2033. Venkat Jasti, CEO, Suven Life, said: “We’re very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”
The granted claims of the patent are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimers disease, attention deficient hyperactivity disorder (ADHD), Huntingtons disease, Parkinsons and Schizophrenia. Suven Life Sciences shares closed higher by Rs1.90 or 0.86 percent at Rs223.35 on BSE.
